IL33 and neoplasm: Notably, Ercolano G., found that blocking PPARγ in IL-33-dependent tumors such as CRC can greatly suppress the IL-33-stimulated release of type 2 cytokines from ILC2, thus decreasing tumor migration (Table 2) [72].